CytomX Therapeutics, Inc. products
Probody - Outsmarting Cancer - Therapeutics. Anti-Cancer
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, their substrates are designed to be cleaved, removing their masks and activating them to bind to their tumor targets, potentially turning the disease against itself.
Pipeline Products
CytomX - CTLA-4 - Directed Probody Therapeutic
Bristol Myers Squibb initiated a Phase 2 randomized 5-arm cohort expansion study in its ongoing first-in-human Phase 1/2a trial of the anti-CTLA-4 Probody BMS-986249, a Probody version of the anti-CTLA-4 antibody Yervoy® (ipilimumab), in combination with Opdivo® (nivolumab) in patients with metastatic melanoma (NCT03369223).
CytomX - PD-L1 - Targeting Probody Therapeutic
CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor activity, while reducing activation of the immune system outside the tumor. Initial clinical translation data presented at SITC confirmed that CX-072 is unmasked, activated and has biological activity in patient tumors while remaining predominantly masked and intact in circulation. Following a recent program and portfolio prioritization, CytomX has also made the strategic decision to terminate the Phase 2 trial of the anti-PD-L1 Probody CX-072 in combination with Yervoy® (ipilimumab) in melanoma. This allows CytomX to focus on its potential first-in-class assets, including the combination of CX-072 and CX-2009.
CytomX - CD71-Directed Probody Drug Conjugate
CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. Historically, CD71 has not been widely pursued as a target given its expression on normal tissues and potential for causing toxicities. CytomX presented initial Phase 1 data at ASCO 2020 validating CD71 as a first-in-class oncology target with encouraging clinical activity observed. CytomX is preparing to advance the CX-2029 into 4 dose-expansion cohorts in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell lymphoma.
CytomX - PD-1-Targeting Probody Therapeutic
CX-188 is our wholly owned PD-1-targeting Probody therapeutic. As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the clinical trials of CX-188, a PD-1 Probody. CytomX may elect to initiate clinical trials of CX-188 in the future.